Armistice Capital’s GT Biopharma GTBP Stock Holding History

Armistice Capital’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-73,334	Closed	-$1.21M	–	245
2023 Q1	$1.21M	Sell	73,334 -39,666	-35%	-$909K	0.02%	134
2022 Q4	$3M	Buy	+113,000	New	+$5.64M	0.05%	111

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFS

Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's GTBP Position: Q2 2023 in Review

Armistice Capital sold out of GT Biopharma (GTBP) in Q2 2023, closing a stake of 73,334 shares — an estimated $1.21M sold.

Armistice Capital first reported a position in GTBP in Q4 2022 and held it in 2 quarters. The position peaked at $3M in Q4 2022. 35 funds tracked by Wall St. Rank hold GTBP as of Q2 2023.

Armistice Capital reported no remaining GT Biopharma position as of Q2 2023 after selling out during the quarter.
Armistice Capital sold 73,334 GT Biopharma shares in Q2 2023, an estimated $1.21M.
Armistice Capital first reported a position in GT Biopharma in Q4 2022 and held it in 2 quarters.
Armistice Capital's GT Biopharma position peaked at $3M in Q4 2022.
35 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2023.

Based on Armistice Capital's 13F filing for Q2 2023, filed 14 Aug 2023.